Natural Capsules

₹140.01As of Sun 8 Nov 2026, 12:00 UTC

NSE:NATCAPSUQHealthcare

Country India

PE (Fwd) —

TSR 10Y CAGR —

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.01

PE TTM —

TSR TTM (32.85%)

Mkt cap ₹1.536B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹155

10.60%

(86.68%)

Price above Reference Value

FY23

FY24

FY25

FY26

Earnings per share₹

19.93

5.97

0.43

(23.78)

0.45%

(70.06%)

(92.72%)

(5572.63%)

Revenue₹B

1.724

1.554

1.692

1.872

27.62%

(9.84%)

8.87%

10.64%

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

1.872

Revenue₹B

—

1.351

1.724

1.554

1.692

1.872

2.042

8.50%

10.64

Revenue growth%

—

27.62

(9.84)

8.87

10.64

9.06

9.75

—

43.17

Gross margin%

—

54.07

52.37

47.35

47.65

43.17

43.12

47.65

(10.89)

Operating margin%

—

14.90

15.54

6.51

4.89

(10.89)

(10.87)

6.51

(9.12)

Net margin%

—

10.30

10.70

3.57

0.25

(9.12)

(9.11)

3.57

—

P/E ratio (avg)x

—

429.1

—

429.1

—

EV/EBITx

—

22.15

—

22.15

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

(16.46)

EPS₹

—

19.84

19.93

5.97

0.43

(16.46)

(17.93)

(72.02%)

—

(3888.32)

EPS growth%

—

0.45

(70.06)

(92.72)

(3888.32)

(8.91)

(81.39)

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

1.00

—

Div yield (avg)%

—

Payout ratio%

—

5.04

5.02

—

2.51

—

10.37

Shares (diluted)M

—

7.012

9.254

9.304

9.836

10.37

◌10.37

10.28%

(5.45)

Buyback yield%

—

(31.97)

(0.54)

(5.72)

(5.45)

◌—

(5.58)

—

D/E ratiox

—

1.452

Enterprise value₹B

—

1.834

2.301

1.452

25.46%

—

LT debt₹M

—

Peers (US$15.82M)

Cap (US$)

Medico Remedies Limited

15.93M

10.86x

Par Drugs and Chemical…

14.28M

10.32x

Bal Pharma Limited

13.93M

18.09x

Turk Ilac Ve Serum…

15.93M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(1.863)

1.973

Own earn%

—

Sh yield%

(5.45)

(5.58)

Owners

Insiders/Inst%

48.46

—

Short interest%

—

SBC / revenue%

1.17

Record

10Y

Profitable years

4/5

Revenue growth years

3/4

EPS growth years

1/4

Dividend streakyrs

Op margin range%

−11–16

$1 testx

—

Incr. ROIC%

—

Natural Capsules Limited engages in the manufacture and sale of hard gelatin and cellulose capsule shells in India and internationally. The company offers bovine spongiform encephalopathy and transmissible spongiform encephalopathy free gelatin, shiny gelatin, sodium lauryl sulfate free gelatin, halal-certified gelatin, fast-release gelatin, printed gelatin/cellulose, vegetarian, and enteric capsule shells.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹1.872B

8.50%

1.00×

Cost of revenue

₹1.064B

14.44%

1.24×

Operating expenses

₹1.012B

17.61%

1.38×

Revenue by region

No breakdown available

Reinvestment returns

No breakdown available